The stock of Skyline Medical Inc (NASDAQ:SKLN) is a huge mover today! About 977,268 shares traded hands. Skyline Medical Inc (NASDAQ:SKLN) has declined 43.76% since April 27, 2016 and is downtrending. It has underperformed by 48.99% the S&P500.
The move comes after 8 months negative chart setup for the $8.02 million company. It was reported on Nov, 30 by Barchart.com. We have $2.41 PT which if reached, will make NASDAQ:SKLN worth $641,600 less.
Analysts await Skyline Medical Inc (NASDAQ:SKLN) to report earnings on March, 16.
According to Zacks Investment Research, “Skyline Medical Inc. is a medical device company. It produces an automated surgical fluid disposal system. The Company has a fully automated surgical fluid disposal device – the Streamway System. Its Streamway System fully automates the collection, measurement and disposal of surgical fluids. Skyline Medical, Inc. is based in Eagan, Minnesota.”
More news for Skyline Medical Inc (NASDAQ:SKLN) were recently published by: Streetinsider.com, which released: “Skyline Medical (SKLN) Reports Approval in Canada to Market STREAMWAY System” on November 22, 2016. Globenewswire.com‘s article titled: “Skyline Medical Effects 1-For-25 Reverse Stock Split” and published on October 27, 2016 is yet another important article.
SKLN Company Profile
Skyline Medical Inc., incorporated on April 23, 2002, is a medical device firm that develops and makes The STREAMWAY System, a solution for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. The Firm distributes these products to hospitals, surgical centers and other medical facilities where bodily and irrigation fluids produced during surgical procedures must be contained, measured, documented and disposed. The Firm also makes and sells two disposable products required for system operation: a bifurcated single procedure filter and tissue trap, and a single use bottle of cleaning solution. Both items are used on a single procedure basis.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.